{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.82","upperLimit":"23.95","value":"15.84"},{"comment":"Insufficient number of events to calculate upper limit of the CI using the K-M method.","groupId":"OG001","lowerLimit":"4.27","upperLimit":"NA","value":"16.82"},{"comment":"Insufficient number of events to calculate upper limit of the CI using the K-M method.","groupId":"OG002","lowerLimit":"1.71","upperLimit":"NA","value":"14.72"},{"groupId":"OG003","lowerLimit":"31.74","upperLimit":"31.74","value":"31.74"},{"comment":"Insufficient number of events to calculate upper limit of the CI using the K-M method.","groupId":"OG004","lowerLimit":"4.30","upperLimit":"NA","value":"14.23"},{"comment":"Insufficient number of events to calculate median and upper limit of the CI using the K-M method.","groupId":"OG005","lowerLimit":"11.60","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"9"}],"units":"Participants"}],"description":"Overall survival is defined as the interval from the date of JCAR017 infusion to the date of death due to any reason. Data from surviving participants was censored at the last time that the participant was known to be alive.\n\nEstimated using Kaplan-Meier product-limit estimates.","dispersionType":"95% Confidence Interval","groups":[{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG000","title":"Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG001","title":"Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG002","title":"Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG003","title":"Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG004","title":"Cohort 5: Primary Central Nervous System Lymphoma"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG005","title":"Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting"}],"paramType":"MEAN","populationDescription":"All participants in the JCAR017 treated set.","reportingStatus":"POSTED","timeFrame":"From the date of JCAR017 infusion to the date of death due to any reason (up to approximately 63 months).","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}